secwatch.observer — SEC 8-K summary
======================================

Issuer:     Werewolf Therapeutics, Inc. (HOWL)
CIK:        0001785530
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0001785530-24-000033
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Werewolf Therapeutics reports Q3 net loss $16.7M; WTX-330 partial response in melanoma
--------------------------------------------------------------------------------

- Net loss $16.7M for Q3 2024 vs $8.3M in Q3 2023; cash $122.8M, runway through Q2 2026.
- WTX-124 monotherapy expansion arms enrolling; initial efficacy data expected H1 2025.
- WTX-330 interim data at SITC: 25 patients, 22-fold higher exposure vs rhIL-12, confirmed partial response in melanoma.
- New preclinical candidate WTX-921 (IL-10) for inflammatory diseases introduced.
- Two WTX-124 patients with confirmed partial responses; one CSCC patient in complete remission >12 months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1785530/000178553024000033/0001785530-24-000033-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1785530/000178553024000033/howl-20241107.htm
  HTML page:      https://secwatch.observer/filing/0001785530-24-000033

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer